These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 20722621)

  • 1. Targeted therapy options for treatment of bone metastases; beyond bisphosphonates.
    Buijs JT; Kuijpers CC; van der Pluijm G
    Curr Pharm Des; 2010; 16(27):3015-27. PubMed ID: 20722621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature.
    Gnant M; Clézardin P
    Cancer Treat Rev; 2012 Aug; 38(5):407-15. PubMed ID: 21983264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging drugs for the treatment of bone metastasis.
    Pantano F; Iuliani M; Zoccoli A; Fioramonti M; De Lisi D; Fioroni I; Ribelli G; Santoni M; Vincenzi B; Tonini G; Santini D
    Expert Opin Emerg Drugs; 2015; 20(4):637-51. PubMed ID: 26113304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapies of bone disease with bisphosphonates.
    Syddall SP; Ottewell PD; Holen I
    Curr Pharm Des; 2010; 16(27):2988-97. PubMed ID: 20722617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of bone-targeted agents on cancer progression and mortality.
    Coleman R; Gnant M; Morgan G; Clezardin P
    J Natl Cancer Inst; 2012 Jul; 104(14):1059-67. PubMed ID: 22752060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and treatment of bone metastases.
    Woodward EJ; Coleman RE
    Curr Pharm Des; 2010; 16(27):2998-3006. PubMed ID: 20722624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonate anticancer activity in prostate cancer and other genitourinary cancers.
    Saad F; Mulders P
    Anticancer Agents Med Chem; 2012 Feb; 12(2):129-36. PubMed ID: 21864229
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
    Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
    Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of castration-resistant prostate cancer: bisphosphonates and emerging therapies.
    Saad F; Colombel M
    Expert Rev Anticancer Ther; 2010 Dec; 10(12):1991-2002. PubMed ID: 21110764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates as anticancer agents in early breast cancer: preclinical and clinical evidence.
    Santini D; Stumbo L; Spoto C; D'Onofrio L; Pantano F; Iuliani M; Fioramonti M; Zoccoli A; Ribelli G; Virzì V; Vincenzi B; Tonini G
    Breast Cancer Res; 2015 Sep; 17(1):121. PubMed ID: 26328589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Bone targeting agents: bisphosphonates].
    Debiais F
    Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bisphosphonates for breast cancer: questions answered, questions remaining.
    Layman R; Olson K; Van Poznak C
    Hematol Oncol Clin North Am; 2007 Apr; 21(2):341-67. PubMed ID: 17512453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Molecular basis of bone metastasis formation and its targeted therapy].
    Tímár J
    Magy Onkol; 2010 Mar; 54(1):59-64. PubMed ID: 20350869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of bisphosphonates and other bone-targeted agents in metastatic bone disease from solid tumors other than breast and prostate cancers.
    Karim SM; Brown J; Zekri J
    Clin Adv Hematol Oncol; 2013 May; 11(5):281-7. PubMed ID: 23880711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Antitumor activity of zoledronic acid].
    Tamási L
    Magy Onkol; 2009 Sep; 53(3):269-71. PubMed ID: 19793692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New strategies for the treatment of metastatic bone disease.
    Pearse RN
    Clin Breast Cancer; 2007 Dec; 8 Suppl 1():S35-45. PubMed ID: 18282368
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antiresorptive effects of bisphosphonates in metastatic bone disease.
    Kanakis I; Kousidou OCh; Karamanos NK
    In Vivo; 2005; 19(1):311-8. PubMed ID: 15796191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New results from the use of bisphosphonates in cancer patients.
    Coleman R; Gnant M
    Curr Opin Support Palliat Care; 2009 Sep; 3(3):213-8. PubMed ID: 19561507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Bisphosphonates in oncology].
    Kurth AA; Heidenreich A; Diel I
    Orthopade; 2007 Feb; 36(2):131-5. PubMed ID: 17252255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone continuum of cancer.
    Lipton A
    Am J Clin Oncol; 2010 Jun; 33(3 Suppl):S1-7. PubMed ID: 20526089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.